Celecoxib blocks cardiac Kv1.5, Kv4.3 and Kv7.1 (KCNQ1) channels. Effects on cardiac action potentials

Journal of Molecular and Cellular Cardiology

Volumn 49, Issue 6, 2010, Pages 984-992

  Macías, Alvaro ^a   Moreno, Cristina ^a   Moral Sanz, Javier ^b   Cogolludo, Angel ^b   David, Miren ^a   Alemanni, Matteo ^c   Pérez Vizcaíno, Francisco ^b   Zaza, Antonio ^c   Valenzuela, Carmen ^a   Gonzalez, Teresa ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Celecoxib; COX 2 inhibitor; Kv1.5; Kv2.1; Kv4.3; Kv7.1; Pharmacology; Voltage gated potassium channel

Indexed keywords

CELECOXIB; POTASSIUM CHANNEL KCNQ1; POTASSIUM CHANNEL KV1.5; POTASSIUM CHANNEL KV4.3; ROFECOXIB; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOSOL; FEMALE; GENETIC TRANSFECTION; GUINEA PIG; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; MALE; MAMMAL CELL; MOUSE; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT;

ACTION POTENTIALS; ANIMALS; GUINEA PIGS; ION CHANNEL GATING; KCNQ1 POTASSIUM CHANNEL; KV1.5 POTASSIUM CHANNEL; MALE; MICE; MYOCYTES, CARDIAC; MYOCYTES, SMOOTH MUSCLE; PYRAZOLES; RATS; RATS, WISTAR; SHAL POTASSIUM CHANNELS; SULFONAMIDES;

CAVIA; MAMMALIA; RATTUS;

EID: 78149414705     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.09.012     Document Type: Article

References (58)

1. Flower R.J. The development of COX2 inhibitors. Nat Rev Drug Discov 2003, 2:179-191.
2. Solomon S.D., Wittes J., Finn P.V., Fowler R., Viner J., Bertagnolli M.M., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008, 117:2104-2113.
3. Mitchell J.A., Warner T.D. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov 2006, 5:75-86.
4. Frolov R.V., Slaughter M.M., Singh S. Effects of celecoxib on ionic currents and spontaneous firing in rat retinal neurons. Neuroscience 2008, 154:1525-1532.
5. Snyders D.J., Tamkun M.M., Bennett P.B. A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression. J Gen Physiol 1993, 101:513-543.
6. Wang Z., Fermini B., Nattel S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res 1993, 73:1061-1076.
7. Kaab S., Dixon J., Duc J., Ashen D., Nabauer M., Beuckelmann D.J., et al. Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 1998, 98:1383-1393.
8. Rosati B., Pan Z., Lypen S., Wang H.S., Cohen I., Dixon J.E., et al. Regulation of KChIP2 potassium channel beta subunit gene expression underlies the gradient of transient outward current in canine and human ventricle. J Physiol 2001, 533:119-125.
9. Sanguinetti M.C., Curran M.E., Zou A., Shen J., Spector P.S., Atkinson D.L., et al. Coassembly of KvLQT1 and minK (IsK) proteins to form cardiac IKs potassium channel. Nature 1996, 384:80-83.
10. Kennel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 2009, 82:2N-9N.
11. Pandit S.V., Berenfeld O., Anumonwo J.M., Zaritski R.M., Kneller J., Nattel S., et al. Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. Biophys J 2005, 88:3806-3821.
12. Archer S.L., Souil E. Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest 1998, 101:2319-2330.
13. Yuan X.J., Wang J., Juhaszova M., Gaine S.P., Rubin L.J. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 1998, 351:726-727.
14. Gonzalez T., Longobardo M., Caballero R., Delpon E., Tamargo J., Valenzuela C. Effects of bupivacaine and a novel local anesthetic, IQB-9302, on human cardiac K+ channels. J Pharmacol Exp Ther 2001, 296:573-583.
15. Cogolludo A., Moreno L., Bosca L., Tamargo J., Perez-Vizcaino F. Thromboxane A2-induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction: role of protein kinase Czeta. Circ Res 2003, 93:656-663.
16. Cogolludo A., Moreno L., Lodi F., Frazziano G., Cobeno L., Tamargo J., et al. Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1 and Kv1.5 channel internalization. Circ Res 2006, 98:931-938.
17. Benitah J.P., Perrier E., Gomez A.M., Vassort G. Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes. J Physiol 2001, 537:151-160.
18. Rocchetti M., Besana A., Mostacciuolo G., Ferrari P., Micheletti R., Zaza A. Diverse toxicity associated with cardiac Na+/K+ pump inhibition: evaluation of electrophysiological mechanisms. J Pharmacol Exp Ther 2003, 305:765-771.
19. Zaza A., Rocchetti M., Brioschi A., Cantadori A., Ferroni A. Dynamic Ca2+-induced inward rectification of K+ current during the ventricular action potential. Circ Res 1998, 82:947-956.
20. Armstrong C.M. Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons. J Gen Physiol 1971, 58:413-437.
21. DeCoursey T.E. Mechanism of K+ channel block by verapamil and related compounds in rat alveolar epithelial cells. J Gen Physiol 1995, 106:745-779.
22. Rauer H., Grissmer S. Evidence for an internal phenylalkylamine action on the voltage-gated potassium channel Kv1.3. Mol Pharmacol 1996, 50:1625-1634.
23. Horrigan F.T., Gilly W.F. Methadone block of K+ current in squid giant fiber lobe neurons. J Gen Physiol 1996, 107:243-260.
24. Brock M.W., Mathes C., Gilly W.F. Selective open-channel block of shaker (Kv1) potassium channels by S-nitrosodithiothreitol (SNDTT). J Gen Physiol 2001, 118:113-134.
25. MacKinnon R., Yellen G. Mutations affecting TEA blockade and ion permeation in voltage activated K+ channels. Science 1990, 250:276-279.
26. Kirsch G.E., Taglialatela M., Brown A.M. Internal and external TEA block in single cloned K+ channels. Am J Physiol 1991, 261:C583-C590.
27. Grissmer S., Cahalan M.D. TEA prevents inactivation while blocking open K+ channels in human T lymphocytes. Biophys J 1989, 55:203-206.
28. Choi K.L., Aldrich R.W., Yellen G. Tetraethylammonium blockade distinguishes two inactivation mechanisms in voltage-activated K+ channels. Proc Natl Acad Sci USA 1991, 88:5092-5095.
29. Catacuzzeno L., Trequattrini C., Petris A., Franciolini F. Mechanism of verapamil block of a neuronal delayed rectifier K channel: active form of the blocker and location of its binding domain. Br J Pharmacol 1999, 126:1699-1706.
30. Snyders D.J., Yeola S.W. Determinants of antiarrhythmic drug action. Electrostatic and hydrophobic components of block of the human cardiac hKv1.5 channel. Circ Res 1995, 77:575-583.
31. Longobardo M., Gonzalez T., Navarro-Polanco R., Caballero R., Delpon E., Tamargo J., et al. Effects of a quaternary bupivacaine derivative on delayed rectifier K+ currents. Br J Pharmacol 2000, 130:391-401.
32. Uebele V.N., England S.K., Gallagher D.J., Snyders D.J., Bennett P.B., Tamkun M.M. Distinct domains of the voltage-gated K+ channel Kvβ1.3 β-subunit affect voltage-dependent gating. Am J Physiol 1998, 274:C1485-C1495.
33. Frolov R.V., Berim I.G., Singh S. Inhibition of delayed rectifier potassium channels and induction of arrhythmia: a novel effect of celecoxib and the mechanism underlying it. J Biol Chem 2008, 283:1518-1524.
34. Frolov R., Bondarenko V., Singh S. Mechanisms of Kv2.1 channel inhibition by celecoxib - modification of gating and channel block. Br J Pharmacol 2009.
35. Woodhull A.M. Ionic blockade of sodium channels in nerve. J Gen Physiol 1973, 61:687-708.
36. Caballero R., Valenzuela C., Longobardo M., Tamargo J., Delpon E. Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac Kv1.5 channels. Br J Pharmacol 1999, 128:1071-1081.
37. Delpon E., Caballero R., Valenzuela C., Longobardo M., Snyders D.J., Tamargo J. Benzocaine enhances and inhibits the K+ current through a human cardiac cloned channel (Kv1.5). Cardiovasc Res 1999, 42:510-520.
38. Zhang X., Anderson J.W., Fedida D. Characterization of nifedipine block of the human heart delayed rectifier, hKv1.5. J Pharmacol Exp Ther 1997, 281:1247-1256.
39. Caballero R., Delpon E., Valenzuela C., Longobardo M., Gonzalez T., Tamargo J. Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization. Mol Pharmacol 2001, 59:825-836.
40. Zhou Y., MacKinnon R. The occupancy of ions in the K+ selectivity filter: charge balance and coupling of ion binding to a protein conformational change underlie high conduction rates. J Mol Biol 2003, 333:965-975.
41. Rich T.C., Snyders D.J. Evidence for multiple open and inactivated states of the hKv1.5 delayed rectifier. Biophys J 1998, 75:183-195.
42. Brueggemann L.I., Mackie A.R., Mani B.K., Cribbs L.L., Byron K.L. Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol Pharmacol 2009, 76:1053-1061.
43. Klein T., Eltze M., Grebe T., Hatzelmann A., Komhoff M. Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Cardiovasc Res 2007, 75:390-397.
44. Davies N.M., McLachlan A.J., Day R.O., Williams K.M. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000, 38:225-242.
45. Nerbonne J.M., Kass R.S. Molecular physiology of cardiac repolarization. Physiol Rev 2005, 85:1205-1253.
46. Tamkun M.M., Knoth K.M., Walbridge J.A., Kroemer H., Roden D.M., Glover D.M. Molecular cloning and characterization of two voltage-gated K+ channel cDNAs from human ventricle. FASEB J 1991, 5:331-337.
47. Van Wagoner D.R., Pond A.L., McCarthy P.M., Trimmer J.S., Nerbonne J.M. Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 1997, 80:772-781.
48. Olson T.M., Alekseev A.E., Liu X.K., Park S., Zingman L.V., Bienengraeber M., et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 2006, 15:2185-2191.
49. Zhang Y., Tao J., Huang H., Ding G., Cheng Y., Sun W. Effects of celecoxib on voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells. Pharmacol Res 2007, 56:267-274.
50. Park S.Y., Kim T.H., Kim H.I., Shin Y.K., Lee C.S., Park M., et al. Celecoxib inhibits Na+ currents in rat dorsal root ganglion neurons. Brain Res 2007, 1148:53-61.
51. Decher N., Kumar P., Gonzalez T., Pirard B., Sanguinetti M.C. Binding site of a novel Kv1.5 blocker: a 'foot in the door' against atrial fibrillation. Mol Pharmacol 2006, 70:1204-1211.
52. Wettwer E., Hala O., Christ T., Heubach J.F., Dobrev D., Knaut M., et al. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation 2004, 110:2299-2306.
53. Varro A., Biliczki P., Iost N., Virag L., Hala O., Kovacs P., et al. Theoretical possibilities for the development of novel antiarrhythmic drugs. Curr Med Chem 2004, 11:1-11.
54. Viswanathan P.C., Shaw R.M., Rudy Y. Effects of IKr and IKs heterogeneity on action potential duration and its rate dependence: a simulation study. Circulation 1999, 99:2466-2474.
55. Antzelevitch C., Dumaine R. Electrical heterogeneity in the heart: Physiological, pharmacological and clinical implications. The handbook of physiology, section 2: the cardiovascular system, volume 1, the heart 2002, 654-692. Oxford University Press, New York. E. Page, H.A. Fozzard, R.J. Solaro (Eds.).
56. Nerbonne J.M., Guo W. Heterogeneous expression of voltage-gated potassium channels in the heart: roles in normal excitation and arrhythmias. J Cardiovasc Electrophysiol 2002, 13:406-409.
57. Eiden C., Peyriere H., Tichit R., Cociglio M., Amedro P., Blayac J.P., et al. Inherited long QT syndrome revealed by antifungals drug-drug interaction. J Clin Pharm Ther 2007, 32:321-324.
58. Ravens U., Cerbai E. Role of potassium currents in cardiac arrhythmias. Europace 2008, 10:1133-1137.